Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

Van De Kerkhof P. C. M., Strohal R., Kubanov A., Valenzuela F., Lee J., Yakusevich V., ...Daha Fazla

LANCET, cilt.386, sa.9993, ss.552-561, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 386 Sayı: 9993
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1016/s0140-6736(14)62113-9
  • Dergi Adı: LANCET
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.552-561
  • Marmara Üniversitesi Adresli: Evet

Özet

Background New therapeutic options are needed for patients with psoriasis. Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis. In this study, we aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population.